| Document |
Document Title |
|
WO/2014/140671A1 |
The present invention relates to new arylaminoalcohol derivatives of formula (I), and to a method for the preparation of such compounds: The invention also relates to the use of these compounds as medicaments, and in particular for the p...
|
|
WO/2014/135437A1 |
The invention relates inter alia to halogen-substituted compounds of general formula (I), in which compounds the groups A1-A4, T, n, W, Q, R1 and Z1-Z3 are defined as cited in the description. Further disclosed are methods for producing ...
|
|
WO/2014/137811A1 |
Chromene derivatives based on a chromene amide isolated from Amyris texana. Also disclosed are compositions containing chromene derivatives (synthetic or natural) based on a chromene amide isolated from Amyris texana. Also methods for re...
|
|
WO/2014/135439A1 |
The invention relates inter alia to halogen-substituted compounds of general formula (II), in which compounds the groups A1-A4, T, n, W, Q, R1 and Z1-Z3 are defined as cited in the description. Further disclosed are methods for producing...
|
|
WO/2014/136672A1 |
(In formula (III), X1 represents an unsubstituted or substituted C1-6 alkyl group or the like; m1 represents an integer of 0-5; A represents an oxygen atom or a sulfur atom; each of R1 and R2 independently represents a hydrogen atom, an ...
|
|
WO/2014/135803A1 |
The invention relates to strains of Toxoplasma gondii isolated from the natural medium thereof for the use of same in the prevention and/or treatment, in a mammal, of eye wounds associated with an infection by an apicomplexa of the Sarco...
|
|
WO/2014/137234A1 |
The invention relates to medicine and specifically to gastroenterology, and is concerned with fasting-diet therapy. A saline laxative is administered to the patient and food intake is ceased. Beginning the first day of fasting, 1.5-2 ...
|
|
WO/2014/134101A1 |
The invention describes a method for treating a parasitic infection or infestation, particularly sea lice, in a fish by administering an effective amount of selamectin.
|
|
WO/2014/132971A1 |
A fused heterocyclic compound or an N-oxide thereof represented by formula (1) has an excellent control effect on pests. [In the formula: A1 represents N or the like; A2 represents NR6 or the like; A3 represents CR12 or the like; R1 repr...
|
|
WO/2014/132972A1 |
A fused heterocyclic compound or an N-oxide thereof represented by formula (1) has an excellent control effect on pests. [In the formula: A1 represents NR8 or the like; A2 and A3 represent N or the like; Q represents O or S; R1 represent...
|
|
WO/2014/132227A1 |
The present invention relates to a non-aqueous composition that comprises a permeation enhancer such as a terpene, for delivering an active ingredient transdermally. The composition comprises at least on one active ingredient, a terpene,...
|
|
WO/2014/128188A1 |
Compounds of formula (I) wherein R1, R2, R3, R4,R5, R6a and R6b are as as defined in the description; or a stereoisomer, salt, tautomer or N-oxide, or a polymorphic crystalline form, a co-crystal or a solvate of a compound or a stereoiso...
|
|
WO/2014/128612A1 |
The invention relates to quinazolin-4-one compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, Formula (I) wherein R1, R2, R3, R5, R6 and L are as defined in the description. Such compounds are s...
|
|
WO/2014/129431A1 |
The invention provides a drug having as the active ingredient a compound having Trk-inhibiting activity in the prevention and/or treatment of Trk-associated diseases, for example, pain, pruritus, lower urinary tract disorders, asthma, al...
|
|
WO/2014/124245A1 |
The invention is directed to compositions and methods related to proteins that are physically associated with ceramide-like glycolipids for use as activators of NKT cells. The compositions and methods of the present invention are useful ...
|
|
WO/2014/123205A1 |
Provided is a condensed heterocyclic compound that is represented by formula (1). In formula (1), R1 represents 1 or more halogen atoms or a C1-C6 alkyl group or the like that may have 1 or more cyclopropyl groups, R2 and R4 represent a ...
|
|
WO/2014/123206A1 |
Provided is a condensed heterocyclic compound that is represented by formula (1). In formula (1), A1 represents NR7 or the like, A2 and A3 represent N or the like, Q represents O or S, R1 represents a C1-C6 chain hydrocarbon group or the...
|
|
WO/2014/121064A1 |
The present invention encompasses methods of using fexinidazole to treat and eliminate and/or cure L. infantum infections in canines.
|
|
WO/2014/121124A1 |
This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therape...
|
|
WO/2014/117236A1 |
The present invention describes an oil-in-water nanoemulsion consisting of 5-40% m/m (mass/mass percent) of at least one surfactant, 1-50% m/m of at least one oil; and optionally approximately 30% of one or more solvents; the invention a...
|
|
WO/2014/115487A1 |
An object is to provide means for precisely treating pneumonia caused by intracellular parasite, protozoa, and/or fungus. A pharmaceutical composition for pneumonia, comprising a compound represented by the following general formula (1) ...
|
|
WO/2014/111666A1 |
The present invention relates to thieno[3,2-d]pyrimidin-4(3H)-one derivatives, to the preparation method thereof, to the pharmaceutical compositions containing said derivatives, as well as to the therapeutic use of same, particularly as ...
|
|
WO/2014/111957A1 |
The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents wherein the drug or therapeutic agents contain at least one carboxylic acid group. The invention also relates to processes for the prep...
|
|
WO/2014/112387A1 |
The purpose of the invention is to provide a novel antitrypanosomal drug. The invention pertains to actinoallolides (A, B, C, D, and/or E), which are novel compounds produced by the actinomycete MK 10-036; to a method for producing said ...
|
|
WO/2014/109375A1 |
Provided are: a substituted pyridazine compound represented by formula (1); and a novel fungicide, particularly an agricultural and horticultural fungicide, which comprises the compound. R1: a halogen atom, a C1-6 alkyl group or the like...
|
|
WO/2014/108168A1 |
The present invention provides compounds of Formula (I) for the treatment of parasitic diseases including malaria, as well as neurodegenerative diseases. Formula (I) wherein R3, R4, X and Y have the meaning given in claim 1.
|
|
WO/2014/100113A2 |
|
|
WO/2014/095845A1 |
The present invention relates to tablets for animals with improved acceptance and good storage stability.
|
|
WO/2014/097338A1 |
A useful composition used for the biological control of the welfare of bees, and for, prophylaxis and treatment of pathological disorders of bees leading to various causes, and particularly on the condition caused by bee paralysis virus ...
|
|
WO/2014/099837A1 |
Disclosed is a method for treating an animal for infection by helmintha which comprises administering to the animal a parasiticidally effective anount of a compound of Formula (1), or a pharmaceutically or veterinarily acceptable salt or...
|
|
WO/2014/098619A1 |
Described herein are transdermal parasiticidal formulations and methods of treatment and use. wherein the formulation is not only able to deliver an agent or agents through the skin layer, but is able to do so through wool, dirt and/or a...
|
|
WO/2014/100486A1 |
The present disclosure describes artemisinin compounds. The compounds can be synthesized using an Ugi synthesis reaction and can be used in the treatment of cancers, parasitic infections and yeast infections.
|
|
WO/2014/098015A1 |
Provided are a 1-aryl-1-heterodiene compound represented by formula (I) or a salt thereof, and a pesticide containing said compound or salt thereof as an active ingredient. In formula (I), Q represents an aryl ring or the like; D2 repres...
|
|
WO/2014/098623A1 |
A method of treating a herd of cattle in a milking shed by injecting an animal at an injection site at or near the rear of the animal with an anthelmintic injectable formulation comprising eprinomectin dissolved in an organic solvent. Th...
|
|
WO/2014/093481A1 |
This invention relates to a veterinary composition comprising a fluorinated cyclopropylphenylpyrazole. The veterinary composition also comprises a veterinary acceptable carrier including a triglyceride, a solvating agent and optonally an...
|
|
WO/2014/090127A1 |
Disclosed are a cyclodextrin carrier-based arteannuin compound conjugate and a preparing method thereof. Molecules of an arteannuin compound are connected by using an ester bond formed between a carboxyl group of the molecules of the art...
|
|
WO/2014/091463A1 |
The present invention relates to the use of recombinant HSP 83-1, MAPK and MAPK3 antigens, proteins present in protozoa of the Leishmania genus, for producing vaccines and a leishmaniasis diagnostic kits for humans and/or dogs. These ant...
|
|
WO/2014/087007A1 |
The disclosure relates to binding molecules, in particular antibodies or antigen-binding fragments thereof, that specifically bind to the merozoite surface protein 3 (MSP3) of Plasmodium spec, in particular Plasmodium falciparum. These m...
|
|
WO/2014/086959A1 |
The present invention relates to compositions and methods for treating coccidiosis in non-human mammals. More particularly, the invention relates to intramuscular compositions and methods for treating coccidiosis with a triazine.
|
|
WO/2014/089570A1 |
The invention provides combinations comprising GDC-0068 or GDC-0941, or a pharmaceutically acceptable salt thereof and MEHD7945A. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer (e.g., t...
|
|
WO/2014/086958A1 |
The invention also relates to improved methods for protecting non-human animals with triazine compounds by intramuscular or subcutaneous injection(s). The invention can be used with various triazines, such as toltrazuril, in different no...
|
|
WO/2014/086960A1 |
The present invention is relative to novel compositions comprising at least one active ingredient of the family of the triazines combined with another active ingredient and specific compounds that allow the reduction of foam formation. M...
|
|
WO/2014/084333A1 |
The present invention addresses the problem of identifying a protein essential for plasmodium in a liver-infection stage to proceed to the next stage, pro viding a test method for searching for a compound obstructing this prote in, and p...
|
|
WO/2014/084471A1 |
The present invention relates to an antimalarial composition containing an N-acetyl-L-Leucyl-L-leucyl-L-norleucinal (ALLN) derivative compound as an active ingredient. The ALLN derivative compound of the present invention can be used as ...
|
|
WO/2014/079937A1 |
The present invention provides compounds of formula (I) wherein R1, R2, R3, R4, n, A1, A2, A3, A4, Y1, Y2, and Y3 are as defined in the claims. The invention also relates to processes and intermediates for preparing these compounds, to i...
|
|
WO/2014/081697A2 |
The present invention relates to novel anthelmintic compounds of formula (I) wherein Y and Z are independently a bicyclic carbocyclic or a bicyclic heterocyclic group, or one of Y or Z is a bicyclic carbocyclic or a bicyclic heterocyclic...
|
|
WO/2014/081922A1 |
The present invention provides compounds that are useful in treating or preventing infection of a mammal by an apicomplexan parasite. The present invention also provides a method of treating infections by an apicomplexan parasite in a ma...
|
|
WO/2014/076261A1 |
The invention concerns a composition made from at least one sulphated polysaccharide, in particular from an algae, and combined with at least one food ingredient. This composition can be used, in particular, in the field of food or in th...
|
|
WO/2014/076150A1 |
The present invention relates to the use of amphoteric polyamidoamines with MW of 10-100 kDa as carriers of antimalarial drugs and to formulations thereof.
|
|
WO/2014/078802A1 |
The present invention provides compounds of formula I: [INSERT FORMULA HERE] or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides p...
|
